HALO

81.57

0.98% 0.79

Dopo l'orario di chiusura: 82.05 0.48 +0.59%

Halozyme Therapeutics Inc (HALO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HALO Giù? Forum Previsione

Precedente Chiudi:

$80.78

Aprire:

$81.5

Volume 24 ore:

2.03M

Relative Volume:

1.17

Capitalizzazione di mercato:

$9.68B

Reddito:

$1.51B

Utile/perdita netta:

$348.84M

Rapporto P/E:

29.34

EPS:

2.7805

Flusso di cassa netto:

$667.65M

1 W Prestazione:

+4.22%

1M Prestazione:

+14.04%

6M Prestazione:

+8.60%

1 anno Prestazione:

+50.44%

Intervallo 1D:

$80.61

$82.26

Intervallo di 1 settimana:

$75.71

$82.26

Portata 52W:

$54.15

$82.26

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Nome

Halozyme Therapeutics Inc

Settore

Healthcare (1094)

Industria

Biotechnology (615)

Telefono

(858) 794-8889

Indirizzo

12390 EL CAMINO REAL, SAN DIEGO, CA

Dipendente

423

Cinguettio

@halozymeinc

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HALO Halozyme Therapeutics Inc	81.57	9.58B	1.51B	348.84M	667.65M	2.7805
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-04	Downgrade	Goldman	Neutral → Sell
2025-10-14	Aggiornamento	Leerink Partners	Underperform → Market Perform
2025-08-06	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-07-10	Ripresa	Goldman	Neutral
2025-05-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-05-13	Downgrade	Leerink Partners	Market Perform → Underperform
2024-10-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-09-19	Downgrade	JP Morgan	Overweight → Neutral
2024-06-07	Downgrade	Piper Sandler	Overweight → Neutral
2024-02-29	Iniziato	TD Cowen	Outperform
2023-07-24	Downgrade	Goldman	Buy → Neutral
2023-07-24	Iniziato	H.C. Wainwright	Buy
2023-05-10	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-03-27	Ripresa	Berenberg	Buy
2023-03-16	Downgrade	SVB Securities	Outperform → Market Perform
2022-12-21	Ripresa	Morgan Stanley	Overweight
2022-11-28	Iniziato	Wells Fargo	Overweight
2022-09-09	Iniziato	Morgan Stanley	Overweight
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-06-14	Iniziato	Evercore ISI	Outperform
2021-05-17	Iniziato	SVB Leerink	Outperform
2021-05-11	Downgrade	Piper Sandler	Overweight → Neutral
2021-01-21	Reiterato	The Benchmark Company	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-07-01	Iniziato	The Benchmark Company	Buy
2020-02-05	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-01-09	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2020-01-08	Iniziato	Goldman	Buy
2019-11-05	Aggiornamento	Barclays	Underweight → Equal Weight
2018-10-19	Ripresa	Piper Jaffray	Neutral
2018-05-11	Downgrade	Barclays	Equal Weight → Underweight
2018-01-24	Iniziato	Goldman	Neutral
2017-10-16	Reiterato	Piper Jaffray	Overweight
2017-01-06	Downgrade	Citigroup	Buy → Neutral
2016-11-03	Iniziato	Deutsche Bank	Buy
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-11-18	Iniziato	Citigroup	Buy
2015-09-22	Iniziato	Barclays	Overweight
2015-06-22	Reiterato	JP Morgan	Overweight
2015-03-03	Reiterato	UBS	Buy
2015-02-18	Reiterato	MLV & Co	Buy
2015-01-08	Reiterato	MLV & Co	Buy

Mostra tutto

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

Jul 06, 2026

Halozyme's Q4 earnings miss, higher royalties drive Y/Y revenues - MSN

Jul 06, 2026

Jul 04, 2026

Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued - Sahm

Jul 04, 2026

Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView

Jul 04, 2026

Jul 03, 2026

Halozyme Therapeutics Operating Chief Caudill to Exit - Moomoo

Jul 03, 2026

Jul 02, 2026

Halozyme stock falls as chief operating officer departs By Investing.com - Investing.com Nigeria

Jul 02, 2026

Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus

Jul 02, 2026

Halozyme stock falls as chief operating officer departs - Investing.com

Jul 02, 2026

Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting - Stock Titan

Jul 02, 2026

Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package - Stock Titan

Jul 02, 2026

Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades - Stock Titan

Jul 02, 2026

Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle - Stock Titan

Jul 02, 2026

Halozyme Therapeutics, Inc. Announces Departure of Cortney Caudill as Senior Vice President, Chief Operating Officer - marketscreener.com

Jul 02, 2026

Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative? - Sahm

Jul 02, 2026

Jun 30, 2026

Halozyme names David Ramsay as president drug delivery - Investing.com UK

Jun 30, 2026

Halozyme names David Ramsay as president drug delivery By Investing.com - Investing.com South Africa

Jun 30, 2026

Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com - Investing.com South Africa

Jun 30, 2026

Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia

Jun 30, 2026

Halozyme director Mahesh Krishnan sells $547,800 in stock - Investing.com UK

Jun 30, 2026

Halozyme (HALO) director exercises options, sells 7,304 shares under plan - Stock Titan

Jun 30, 2026

Press Release: Halozyme Appoints David Ramsay as President Drug Delivery - Moomoo

Jun 30, 2026

Jun 29, 2026

Small Cap Core Portfolio I's Halozyme Therapeutics Inc(HALO) Holding History - GuruFocus

Jun 29, 2026

Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView

Jun 25, 2026

RV7 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Price to book forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView

Jun 24, 2026

Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView

Jun 24, 2026

Price to earnings forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView

Jun 24, 2026

Jun 22, 2026

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection - GlobeNewswire Inc.

Jun 22, 2026